View abstract

This abstract is assigned to session Free Papers - Oral Presentations II

Presentation preference	Oral presentation
Title	Adalimumab biosimilars have similar disease relapse rates to originator adalimumab when treating non-infectious uveitis
Accept poster if oral is not possible ?	No

Purpose	To compare the efficacy in achieving and maintaining control of inflammation between adalimumab biosimilars and originator adalimumab, as initial biologic treatment among adult patients with refractory non-infectious uveitis (NIU).
Methods	A multi-center retrospective cohort study of 260 eyes of 148 patients diagnosed with NIU who received initial biologic treatment of either originator adalimumab or a biosimilar. Events of uveitis relapse were noted per-eye following initiation of adalimumab treatment. Relapse rates and time to first relapse by 12 months, were compared between eyes treated with originator adalimumab or a biosimilar.
Results	Eyes were treated with either originator adalimumab (n=193, 74.23%) or a biosimilar (n=67, 25.77%). Median follow-up from baseline for patients who did not relapse was 24.0 [IQR 18.0, 24.0]. Uveitis relapses occurred in 97 eyes (37.31%, 76 in the adalimumab group and 21 in the biosimilar group). By twelve months, the estimated relapse rate was 24.2% in the adalimumab group vs. 28.3% in the biosimilar group (Relative risk=1.17, 95% CI 0.58 to 1.77). The average time to relapse by 12 months follow-up for the adalimumab group was 4.91 months compared with 5.04 months in the biosimilars group (mean difference 0.13 months, 95% CI -1.33 1.54 months).
Conclusion	Our study suggest that by twelve months use, biosimilar adalimumab agents were not inferior to originator adalimumab in preventing disease relapse among patients with refractory NIU. These results support the use of biosimilar adalimumab for treating NIU.
Conflict of interest	No

1

Last name	TOMKINS-NETZER
Initials of first name(s)	O
Department	Department of Ophthalmology, Lady Davis Carmel Medical Center
City	Haifa
Country	Israel

2

Last name	Sharon
Initials of first name(s)	Y
Department	Department of Ophthalmology, Rabin Medical Center
City	Petach Tikva
Country	Israel

3

Last name	Niederer
Initials of first name(s)	R
Department	Department of Ophthalmology, Auckland District Health Board
City	Auckland
Country	New Zealand

4

Last name	Amar
Initials of first name(s)	R
Department	Department of Ophthalmology, Hadassah Medical Center
City	Jerusalem
Country	Israel

5

Last name	Sar
Initials of first name(s)	S
Department	Department of Ophthalmology, Lady Davis Carmel Medical Center
City	Haifa
Country	Israel

6

Last name	Habot-Wilner
Initials of first name(s)	Z
Department	Division of Ophthalmology, Tel Aviv Sourasky Medical Center
City	Tel Aviv
Country	Israel

7

Last name	Gepstein
Initials of first name(s)	R
Department	Department of Ophthalmology, Meir Medical Center
City	Kfar Sava
Country	Israel

8

Last name	Shyriaieva
Initials of first name(s)	H
Department	Department of Ophthalmology, Emek Medical Center
City	Afula
Country	Israel

9

Last name	Diab
Initials of first name(s)	R
Department	Department of Ophthalmology, Lady Davis Carmel Medical Center
City	Haifa
Country	Israel

10

Last name	Corredores
Initials of first name(s)	J
Department	Department of Ophthalmology, Hadassah Medical Center
City	Jerusalem
Country	Israel

11

Last name	Cohen
Initials of first name(s)	S
Department	Division of Ophthalmology, Tel Aviv Sourasky Medical Center
City	Tel Aviv
Country	Israel

12

Last name	Barnett-Griness
Initials of first name(s)	O
Department	Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center
City	Haifa
Country	Israel

13

Last name	Kramer
Initials of first name(s)	M
Department	Department of Ophthalmology, Rabin Medical Center
City	Petach Tikva
Country	Israel